Increased dosage of infliximab is a potential cause of  pneumonia by unknown
Iwama et al. Gut Pathog  (2016) 8:2 
DOI 10.1186/s13099-016-0086-4
CASE REPORT
Increased dosage of infliximab is 
a potential cause of Pneumocystis carinii 
pneumonia
Takuya Iwama, Aki Sakatani, Mikihiro Fujiya*, Kazuyuki Tanaka, Shugo Fujibayashi, Yoshiki Nomura, 
Nobuhiro Ueno, Shin Kashima, Takuma Gotoh, Junpei Sasajima, Kentaro Moriichi and Katsuya Ikuta
Abstract 
Methods: Pneumocystis carinii pneumonia occasionally appears in immunodeficient patients. While several reports 
have shown that Pneumocystis carinii pneumonia occurred in the early phase of starting infliximab treatment in 
patients with Crohn’s disease (CD), the present case suggests for the first time that an increased dosage of infliximab 
may also lead to pneumonia.
Results: A 51-year-old male had been taking 5 mg of infliximab for the treatment of CD for 10 years with no adverse 
events. Beginning in September 2013, the dose of infliximab had to be increased to 10 mg/kg because his status 
worsened. Thereafter, he complained of a fever and cough, and a CT scan revealed ground-glass opacities in the lower 
lobes of the bilateral lung with a crazy-paving pattern. Bronchoscopy detected swelling of the tracheal mucosa with 
obvious dilations of the vessels. A polymerase chain reaction using a bronchoalveolar lavage fluid sample detected 
specific sequences for Pneumocystis jirovecii; thus he was diagnosed with Pneumocystis carinii (jirovecii) pneumonia. 
After discontinuing infliximab and starting antibiotic treatment, his symptoms and CT findings were dramatically 
improved.
Conclusions: The administration of an increased dosage of infliximab can cause Pneumocystis carinii pneumonia in 
CD patients.
© 2016 Iwama et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Pneumocystis carinii pneumonia occasionally appears in 
immunodeficient patients, particularly with the admin-
istration of chemotherapy. While several reports have 
shown that infliximab treatment [1–5], which is gener-
ally used for the treatment of rheumatoid arthritis and 
Crohn’s disease, can lead to Pneumocystis carinii pneu-
monia [6–12], to the best of our knowledge, no case has 
demonstrated the development of pneumonia due to an 
increased dosage of infliximab treatment. The present 
case suggests that an increased dosage of infliximab is a 
potential cause of Pneumocystis carinii pneumonia.
Case
A 51-year-old male was suffering Crohn’s disease (CD) 
since 1990. The patient’s weight was 67  kg. He had the 
inflammatory type of Crohn’s disease, and the area of 
his lesion was the colon and small intestine. He had no 
complications, including intra- or extraenteral lesions, or 
any other systemic disorders. He had been taking 5 mg/
kg of infliximab (total 400  mg) since 2004 and 0.15  g/
day of 6-mercaptopurine since 2005. However, he com-
plained of abdominal pain, his Harvey–Bradshaw index 
scores increased from 5 to 13, and he subsequently began 
taking 10  mg/kg of infliximab (total 650  mg) from Sep-
tember 2013. In January 2014, he complained of a fever 
and cough. Laboratory tests on this admission showed 
high levels of C-reactive protein and anti-mycoplasma 
antibody while other examination items, including the 
white blood cell count and T-SPOT, were unremarkable. 
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A computed tomography (CT) scan revealed ground-
glass opacities in the lower lobes of the bilateral lung with 
a crazy-paving pattern (Fig. 1a). Bronchoscopy detected 
swelling of the tracheal mucosa with obvious dilations of 
the vessels (Fig. 2). A bronchoalveolar lavage fluid sam-
ple obtained during bronchoscopy included 255  cells/
field with 80  % macrophages, 12  % lymphocytes and 
8 % neutrophils. A polymerase chain reaction using the 
bronchoalveolar lavage fluid sample detected specific 
sequences for Pneumocystis jirovecii. Taken together, he 
was diagnosed as having pneumonia due to the com-
bined infection of Mycoplasma and Pneumocystis carinii 
(jirovecii). The patient stopped infliximab administration 
and took 2 g/day of ceftriaxone, 500 mg/day of azithro-
mycin and 400  mg/80  mg/day of sulfamethoxazole/tri-
methoprim; thereafter his symptoms including a fever 
and cough improved. CT after the antibiotic therapy 
showed a significant improvement of the ground-glass 
opacities in the lower lobes of the bilateral lung (Fig. 1b).
Discussion
The present report demonstrated a case of Pneumocystis 
carinii pneumonia due to the increased dosage of inflixi-
mab. While several cases have demonstrated pneumonia 
due to Pneumocystis carinii after infliximab treatment, to 
the best of our knowledge, this is the first case in which 
an increased dosage of infliximab triggered pneumonia. 
A summary of previously reported cases and our case of 
Pneumocystis carinii pneumonia in CD patients is shown 
in Table 1.
Of the seven cases, five were male and two were female. 
The age ranged from 8 to 77 years. While Pneumocystis 
carinii pneumonia appeared at 4  weeks to 29  months 
after starting infliximab treatment in previous reports, 
the present case exhibited pneumonia at 120  months 
after starting infliximab treatment, at 102  months after 
starting the 6-mercaptopurine treatment, 24 weeks after 
starting an increased dosage of infliximab from 5 to 
10 mg/kg. This suggests that an increased dosage of inf-
liximab is a potential cause of immunodeficiency, lead-
ing to Pneumocystis carinii pneumonia. Notably, all cases 
developing Pneumocystis carinii pneumonia took immu-
nomodulators and/or steroids, suggesting that the com-
bined use of these drugs is a risk for pneumonia. Because 
sulfamethoxazole/trimethoprim was effective for all 
cases, antibiotics should be immediately administered 
after the diagnosis of Pneumocystis carinii pneumonia.
Fig. 1 Computed tomography findings of the chest. Ground-glass opacities were seen in the lower lobes of the bilateral lung with a crazy-paving 
pattern on admission (a). Ground-glass opacities were improved after antibiotic therapy (b)
Fig. 2 Bronchoscopy finding. Swelling and obvious dilations of the 
vessels were seen in the tracheal mucosa on admission
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Conclusions
The findings of the present case suggest that the admin-
istration of an increased dosage of infliximab, as well as a 
general dose of infliximab, can cause Pneumocystis cari-
nii pneumonia in CD patients, particularly in patients 
taking immunomodulators and/or steroids, illustrating 
the need for follow up, including pulmonary symptoms 
and CT examinations, when increasing the dosage of inf-
liximab in CD patients.
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Table 1 Date on pneumocystis pneumonia during administrarion of infliximab
ST sulfamethoxazole/trimethoprim, PSL prednisolone, mPSL methylprednisolone, PM pentamidine, AZA azathioprine, 5-ASA mesalazine, 6-MP 6mercaptopurine, ND 
not described






IFX duration Dose of IFX Concomitant 
drug(s)
Medication Clinical course
1 Seddik et al. [6] 2004 Male 29 ND 1 month 5 mg/kg PSL + AZA ST 2 weeks alive
2 Velayos et al. [7] 2004 Male 19 2 years 2 years 
3 months
5 mg/kg AZA ST + PSL 2 weeks alive
3 Kaur et al. [8] 2004 Male 59 3 weeks 9 weeks ND PSL ST + PM 1 month died
4 Stratakos et al. [9] 2005 Female 77 9 months 8 months 5 mg/kg mPSL + AZA ST 6 month alive
5 Itaba et al. [10] 2007 Female 57 21 years 5 weeks 5 mg/kg PSL + AZA ST + mPSL 4 month alive
6 金井 et al. [11] 2009 Male 69 44 years 4 weeks 5 mg/kg 5-ASA + PSL ST + mPSL 6 month alive
7 Tshudy et al. [12] 2010 Male 8 6 years 15 months 5 mg/kg None ST 4 weeks alive
8 Present case 2014 Male 51 24 years 10 years 10 mg/kg 6-MP (0.15 g/
day)
ST 1 year 5 month 
alive
